- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Walgreens partners with Chicago Public Schools and city health department on Tdap vaccination project
- PhRMA report lists 271 vaccines in development
TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.
Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.
"This second U.S. approval for Eylea provides physicians and patients with a new treatment option for the treatment of macular edema following CRVO," Regeneron chief scientific officer and Regeneron Labs president George Yancopoulos said.